Impact of Cysteine Residues on MHC Binding Predictions and Recognition by Tumor-Reactive T Cells

Key Points Oxidation of Cys-containing peptides can inhibit MHC binding and T cell responses. Effects of inhibiting oxidation of Cys-containing peptides on binding and recognition are detailed. The availability of MHC-binding prediction tools has been useful in guiding studies aimed at identifying candidate target Ags to generate reactive T cells and to characterize viral and tumor-reactive T cells. Nevertheless, prediction algorithms appear to function poorly for epitopes containing cysteine (Cys) residues, which can oxidize and form disulfide bonds with other Cys residues under oxidizing conditions, thus potentially interfering with their ability to bind to MHC molecules. Analysis of the results of HLA-A*02:01 class I binding assays carried out in the presence and absence of the reducing agent 2-ME indicated that the predicted affinity for 25% of Cys-containing epitopes was underestimated by a factor of 3 or more. Additional analyses were undertaken to evaluate the responses of human CD8+ tumor-reactive T cells against 10 Cys-containing HLA class I–restricted minimal determinants containing substitutions of α-aminobutyric acid (AABA), a cysteine analogue containing a methyl group in place of the sulfhydryl group present in Cys, for the native Cys residues. Substitutions of AABA for Cys at putative MHC anchor positions often significantly enhanced T cell recognition, whereas substitutions at non-MHC anchor positions were neutral, except for one epitope where this modification abolished T cell recognition. These findings demonstrate the need to evaluate MHC binding and T cell recognition of Cys-containing peptides under conditions that prevent Cys oxidation, and to adjust current prediction binding algorithms for HLA-A*02:01 and potentially additional class I alleles to more accurately rank peptides containing Cys anchor residues.

[1]  S. Rosenberg,et al.  Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen , 1996, The Journal of experimental medicine.

[2]  Bjoern Peters,et al.  Predicting T cell recognition of MHC class I restricted neoepitopes , 2018, Oncoimmunology.

[3]  Bjoern Peters,et al.  HLA Class I Alleles Are Associated with Peptide-Binding Repertoires of Different Size, Affinity, and Immunogenicity , 2013, The Journal of Immunology.

[4]  J. Shabanowitz,et al.  Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development. , 1998, Journal of immunology.

[5]  C. Pabo,et al.  The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. , 1993, Genes & development.

[6]  Deborah Hix,et al.  The immune epitope database (IEDB) 3.0 , 2014, Nucleic Acids Res..

[7]  Clemencia Pinilla,et al.  Measurement of MHC/Peptide Interactions by Gel Filtration or Monoclonal Antibody Capture , 2013, Current protocols in immunology.

[8]  A. Vitiello,et al.  The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. , 1994, Journal of immunology.

[9]  T. Boon,et al.  An Antigenic Peptide Produced by Peptide Splicing in the Proteasome , 2004, Science.

[10]  Jennifer G. Abelin,et al.  Mass Spectrometry Profiling of HLA‐Associated Peptidomes in Mono‐allelic Cells Enables More Accurate Epitope Prediction , 2017, Immunity.

[11]  Taku Suto,et al.  An automated prediction of MHC class I-binding peptides based on positional scanning with peptide libraries , 2000, Immunogenetics.

[12]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[13]  Jonathan W. Yewdell,et al.  Immune recognition of a human renal cancer antigen through post-translational protein splicing , 2004, Nature.

[14]  M. A. Saper,et al.  Structure of the human class I histocompatibility antigen, HLA-A2 , 1987, Nature.

[15]  D. Jäger,et al.  Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes , 1998, The Journal of experimental medicine.

[16]  P. Coulie,et al.  A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Andrew Sewell,et al.  Structural and kinetic basis for heightened immunogenicity of T cell vaccines , 2005, The Journal of experimental medicine.

[18]  V. Cerundolo,et al.  Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL1 , 2000, The Journal of Immunology.

[19]  D. Madden.  The three-dimensional structure of peptide-MHC complexes. , 1995, Annual review of immunology.

[20]  J. Sidney,et al.  The role of MHC class I allele Mamu-A*07 during SIVmac239 infection , 2011, Immunogenetics.

[21]  Søren Buus,et al.  Peptide binding specificity of major histocompatibility complex class I resolved into an array of apparently independent subspecificities: quantitation by peptide libraries and improved prediction of binding , 1996, European journal of immunology.

[22]  Nathalie Vigneron,et al.  Database of T cell-defined human tumor antigens: the 2013 update. , 2013, Cancer immunity.

[23]  A Sette,et al.  Two complementary methods for predicting peptides binding major histocompatibility complex molecules. , 1997, Journal of molecular biology.

[24]  Andrew R. Jones,et al.  Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations , 2014, Nucleic Acids Res..

[25]  J. Gartner,et al.  Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer , 2019, Cancer Immunology Research.

[26]  O. Lund,et al.  The MHC Motif Viewer: A Visualization Tool for MHC Binding Motifs , 2010, Current protocols in immunology.

[27]  V. Gnau,et al.  Peptide motifs of HLA-A1,-A11,-A31, and-A33 molecules , 1994, Immunogenetics.

[28]  S Walz,et al.  Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy , 2014, Leukemia.

[29]  Morten Nielsen,et al.  Automated benchmarking of peptide-MHC class I binding predictions , 2015, Bioinform..

[30]  J. Sidney,et al.  Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules , 1993, Cell.

[31]  J. Yewdell,et al.  Modification of Cysteine Residues In Vitro and In Vivo Affects the Immunogenicity and Antigenicity of Major Histocompatibility Complex Class I–restricted Viral Determinants , 1999, The Journal of experimental medicine.

[32]  R A Houghten,et al.  Rapid identification of high affinity peptide ligands using positional scanning synthetic peptide combinatorial libraries. , 1992, BioTechniques.

[33]  Morten Nielsen,et al.  Dataset size and composition impact the reliability of performance benchmarks for peptide-MHC binding predictions , 2014, BMC Bioinformatics.

[34]  Morten Nielsen,et al.  MHC-I Ligand Discovery Using Targeted Database Searches of Mass Spectrometry Data: Implications for T-Cell Immunotherapies. , 2017, Journal of proteome research.

[35]  S Brunak,et al.  Quantitative predictions of peptide binding to MHC class I molecules using specificity matrices and anchor-stratified calibrations. , 2001, Tissue antigens.

[36]  Jennifer G. Abelin,et al.  Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction. , 2019, Immunity.

[37]  H. Rammensee,et al.  SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.

[38]  John Sidney,et al.  Two MHC Class I Molecules Associated with Elite Control of Immunodeficiency Virus Replication, Mamu-B*08 and HLA-B*2705, Bind Peptides with Sequence Similarity12 , 2009, The Journal of Immunology.

[39]  Jeffrey K. Mito,et al.  An Antigen Produced by Splicing of Noncontiguous Peptides in the Reverse Order , 2006, Science.

[40]  S. Lemieux,et al.  MHC class I-associated peptides derive from selective regions of the human genome. , 2016, The Journal of clinical investigation.

[41]  Bent K. Jakobsen,et al.  Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions , 2008, The Journal of Immunology.

[42]  Clemencia Pinilla,et al.  Characterization of the peptide-binding specificity of the chimpanzee class I alleles A*0301 and A*0401 using a combinatorial peptide library , 2007, Immunogenetics.

[43]  J. Shabanowitz,et al.  Cutting edge: the HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique. , 1999, Journal of immunology.

[44]  S. Rosenberg,et al.  An antigenic peptide produced by reverse splicing and double asparagine deamidation , 2011, Proceedings of the National Academy of Sciences.

[45]  M. Perkins,et al.  Chemical methods for mapping cysteine oxidation. , 2018, Chemical Society reviews.

[46]  T. Schumacher,et al.  Differential Kinetics of Antigen-Specific CD4+ and CD8+ T Cell Responses in the Regression of Retrovirus-Induced Sarcomas1 , 2002, The Journal of Immunology.

[47]  Bjoern Peters,et al.  Automatic Generation of Validated Specific Epitope Sets , 2015, Journal of immunology research.

[48]  H. Rammensee,et al.  Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules , 1991, Nature.

[49]  Richard A. Morgan,et al.  Primary Human Lymphocytes Transduced with NY-ESO-1 Antigen-Specific TCR Genes Recognize and Kill Diverse Human Tumor Cell Lines , 2005, The Journal of Immunology.

[50]  Bjoern Peters,et al.  A Quantitative Analysis of the Variables Affecting the Repertoire of T Cell Specificities Recognized after Vaccinia Virus Infection1 , 2007, The Journal of Immunology.

[51]  J. Gartner,et al.  Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers , 2019, The Journal of clinical investigation.

[52]  Bjoern Peters,et al.  Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries , 2008, Immunome research.